Importance of factor Xa in determining the procoagulant activity of whole-blood clots.
about
Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysisSynthetic and recombinant antithrombin drugs.Activation-dependent exposure of the inter-EGF sequence Leu83-Leu88 in factor Xa mediates ligand binding to effector cell protease receptor-1.Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases.Urinary Prothrombin Fragment 1+2 in relation to Development of Non-Symptomatic and Symptomatic Venous Thromboembolic Events following Total Knee ReplacementXimelagatran: the first oral direct thrombin inhibitor.New anticoagulants: beyond heparin, low-molecular-weight heparin and warfarinRivaroxaban delivery and reversal at a venous flow rateThe coagulation factor Xa/protease activated receptor-2 axis in the progression of liver fibrosis: a multifaceted paradigm.The discovery and development of rivaroxaban.Oral anticoagulants in older adults with atrial fibrillation.Laboratory assessment of rivaroxaban: a review.Pathophysiology of Cardiopulmonary Bypass: Current Strategies for the Prevention and Treatment of Anemia, Coagulopathy, and Organ Dysfunction.Evaluation of novel factor Xa inhibitors from Oxya chinensis sinuosa with anti-platelet aggregation activity.The use of prothrombin(S525C) labeled with fluorescein to directly study the inhibition of prothrombinase by antithrombin during prothrombin activation.Analysis of the kinetics of prothrombin activation and evidence that two equilibrating forms of prothrombinase are involved in the process.The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model.
P2860
Q28187597-5FE91A71-C57C-4D66-9DD5-FD91E2796FD0Q33367033-C0ACC70C-A796-4A6E-8FD9-A967D30300D9Q34420071-2D5A2518-3CE1-4614-BDFC-F07F7625CB5FQ34549913-CB1F965F-4ED7-4844-9BA4-B694ABE63373Q35367506-2395D919-0BAF-48BE-A5FD-A5B0BE126AF3Q35753482-F9F821C7-6A0D-432D-BFD5-E472F143019EQ36042279-6523E1A1-20B4-4660-BCFB-0D3581A32689Q36775716-31C7A48E-EDE7-4D8D-8092-774547F5721FQ37646912-EAA8F9C6-A1C8-4672-A4BE-396D0D3F45A6Q37857332-9BE2BCE0-E9D6-4E6C-AC1F-0F0B47E054EDQ38076076-7FABBA90-C85E-48F2-9F9E-2446890E2EBDQ38119016-93EC22F5-57F8-4423-97AD-47351E8DC14BQ38215982-1C9D3705-1D56-406B-9F70-A65AA902F903Q41366810-57B909DD-E903-4900-802A-2079F8C5BE71Q43560091-6E34116B-3DFE-44F4-A6B1-91268BC7D0DEQ44258994-33E8F211-800C-4AFF-8374-FC4BE4A470C5Q44518890-8FCAC06F-F02D-42CA-B97C-1390E18E5E52
P2860
Importance of factor Xa in determining the procoagulant activity of whole-blood clots.
description
1993 nî lūn-bûn
@nan
1993 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Importance of factor Xa in determining the procoagulant activity of whole-blood clots.
@ast
Importance of factor Xa in determining the procoagulant activity of whole-blood clots.
@en
type
label
Importance of factor Xa in determining the procoagulant activity of whole-blood clots.
@ast
Importance of factor Xa in determining the procoagulant activity of whole-blood clots.
@en
prefLabel
Importance of factor Xa in determining the procoagulant activity of whole-blood clots.
@ast
Importance of factor Xa in determining the procoagulant activity of whole-blood clots.
@en
P2093
P2860
P356
P1476
Importance of factor Xa in determining the procoagulant activity of whole-blood clots.
@en
P2093
D R Abendschein
J E Siegel
J P Miletich
P R Eisenberg
P2860
P304
P356
10.1172/JCI116404
P407
P577
1993-05-01T00:00:00Z